Diabetes is a chronic disease currently affecting over 420 million people worldwide. Among its most frequent and complex complications are diabetic foot ulcers, which increase the risk of amputation and significantly impact quality of life. However, there is an option that has changed the outlook for thousands of patients: Heberprot-P®, a Cuban medical innovation for the treatment of these lesions.
A comprehensive approach to a serious complication
Developed by Cuba’s prestigious Center for Genetic Engineering and Biotechnology, Heberprot-P® contains recombinant human epidermal growth factor and is administered through direct infiltration into the lesion, promoting rapid and deep healing from within.As part of a comprehensive medical program, this treatment is carried out by specialists from the Institute of Angiology and Vascular Surgery and the National Institute of Endocrinology. Its clinical use has shown positive results in thousands of patients, helping to:
- Reduce the need for amputations
- Shorten healing time
- Decrease the risk of infections and recurrences
- Lower hospitalization-related costs
A program that supports every step
The Heberprot-P® treatment is offered as part of a structured program that includes:- Initial evaluation: specialist consultations, complementary tests, and procedures to prepare the affected areas.
- Medication application: direct infiltration of Heberprot-P® into the ulcers, under medical supervision and continuous clinical monitoring.
Regain mobility. Prevent amputation. Walk again.
On the path to a healthier life, Cuba offers an effective and unique solution. If you or a loved one are living with this diabetes complication, you can access Heberprot-P® treatment through the Cuban Medical Services Trading Corporation, S.A.📩 Contact us at: smc@smcsalud.cu
We are here to support your step toward recovery.
By: MSc. Dr. Patricia Alonso Galbán
Marketing and Communication Specialist, CSMC, S.A.